52 results on '"Relling, Mary V."'
Search Results
2. Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children’s Research Hospital
3. Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia
4. Correction: Outstanding outcomes with two low intensity regimens in children with low-risk B-ALL: a report from COG AALL0932
5. Pharmacotypes across the genomic landscape of pediatric acute lymphoblastic leukemia and impact on treatment response
6. The genomic landscape of pediatric acute lymphoblastic leukemia
7. Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia
8. Noncoding genetic variation in GATA3 increases acute lymphoblastic leukemia risk through local and global changes in chromatin conformation
9. Pharmacodynamics of cerebrospinal fluid asparagine after asparaginase
10. Profiling chromatin accessibility in pediatric acute lymphoblastic leukemia identifies subtype-specific chromatin landscapes and gene regulatory networks
11. Network-based systems pharmacology reveals heterogeneity in LCK and BCL2 signaling and therapeutic sensitivity of T-cell acute lymphoblastic leukemia
12. Integrative genomic analyses reveal mechanisms of glucocorticoid resistance in acute lymphoblastic leukemia
13. Identification of four novel associations for B-cell acute lymphoblastic leukaemia risk
14. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia
15. Concordance between glucose-6-phosphate dehydrogenase (G6PD) genotype and phenotype and rasburicase use in patients with hematologic malignancies
16. Multiplex assessment of protein variant abundance by massively parallel sequencing
17. The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia
18. Differential effects of thiopurine methyltransferase (TPMT) and multidrug resistance-associated protein gene 4 (MRP4) on mercaptopurine toxicity
19. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
20. Pharmacogenomics in the clinic
21. Inherited coding variants at the CDKN2A locus influence susceptibility to acute lymphoblastic leukaemia in children
22. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells
23. Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia
24. Evidence synthesis and guideline development in genomic medicine: current status and future prospects
25. Erratum to: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments
26. Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse
27. Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments
28. Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells
29. Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia
30. Germline genomic variants associated with childhood acute lymphoblastic leukemia
31. BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
32. Are children with lesser-risk B-lineage acute lymphoblastic leukemia curable with antimetabolite therapy?
33. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia
34. Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypes
35. Moving towards individualized medicine with pharmacogenomics
36. Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells
37. Polymorphisms in the MLL breakpoint cluster region (BCR)
38. Pharmacogenetics and cancer therapy
39. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia
40. Gazing into a crystal ball–cancer therapy in the post-genomic era
41. Pharmacokinetics of paclitaxel in an anephric patient
42. Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans*
43. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors*
44. Clinical Pharmacokinetics of Paclitaxel
45. Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics
46. Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2* activities
47. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects
48. Age-related differences in hepatic drug clearance in children: Studies with lorazepam and antipyrine
49. Hepatic drug clearance in children with leukemia: Changes in clearance of model substrates during remission-induction therapy
50. Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.